Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells $353,771.40 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 9,220 shares of Liquidia stock in a transaction on Monday, April 13th. The shares were sold at an average price of $38.37, for a total value of $353,771.40. Following the completion of the transaction, the insider owned 173,270 shares in the company, valued at $6,648,369.90. The trade was a 5.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Performance

Shares of NASDAQ:LQDA opened at $41.40 on Friday. The firm has a market capitalization of $3.65 billion, a PE ratio of -49.88 and a beta of 0.45. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. The business has a 50-day moving average of $36.63 and a two-hundred day moving average of $33.14. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $46.67.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The business had revenue of $92.02 million for the quarter, compared to analyst estimates of $87.49 million. Liquidia’s quarterly revenue was up 3072.4% compared to the same quarter last year. As a group, research analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current year.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Earnings beat and improving near‑term fundamentals — Liquidia reported stronger‑than‑expected revenue and EPS for the quarter (revenue and EPS beat consensus), which supports upside vs. expectations and likely underpins buying momentum. MarketBeat: Liquidia Stock
• Positive Sentiment: Analyst support — multiple firms have reiterated or raised ratings/targets (including upgrades and higher price targets), giving institutional and retail buyers a constructive research backdrop. MarketBeat: Analyst Coverage
• Neutral Sentiment: High institutional ownership (~64.5%) and selective inflows — large holders can stabilize the stock, so insider sales don’t automatically translate into sustained selling pressure if institutions hold or add. MarketBeat: Institutional Holdings
• Negative Sentiment: Concentrated insider selling — several executives sold meaningful blocks of shares (CEO and CFO among them) under pre‑arranged Rule 10b5‑1 plans; the scale and timing of these sales can create negative investor perception despite being planned. SEC Filing: Kaseta Sale
• Negative Sentiment: CEO/C-suite sales add to concern — CEO Roger Jeffs disclosed multi‑date sales (including a 25,000‑share block), which, together with other officer transactions, may cap upside near recent highs. SEC Filing: Jeffs Sale

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Needham & Company LLC boosted their price objective on shares of Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Thursday, January 22nd. HC Wainwright lifted their target price on shares of Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, March 6th. Wells Fargo & Company increased their price target on Liquidia from $44.00 to $51.00 and gave the company an “overweight” rating in a report on Monday, March 23rd. Finally, Oppenheimer raised their price objective on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research report on Thursday, March 12th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $43.44.

Institutional Trading of Liquidia

Several institutional investors have recently added to or reduced their stakes in LQDA. Federated Hermes Inc. bought a new stake in shares of Liquidia in the 3rd quarter worth about $7,290,000. Caprock Group LLC bought a new position in shares of Liquidia during the third quarter worth about $37,114,000. Farallon Capital Management LLC lifted its position in shares of Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after purchasing an additional 4,326,876 shares during the last quarter. Apis Capital Advisors LLC acquired a new position in Liquidia in the third quarter worth about $9,569,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Liquidia in the third quarter worth about $2,026,000. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).